[{"id":"937bec61-abb0-4838-bc7e-ee7138f0f459","acronym":"MED20-165","url":"https://clinicaltrials.gov/study/NCT04512716","created_at":"2021-01-18T21:37:46.095Z","updated_at":"2024-07-02T16:35:15.633Z","phase":"Phase 1","brief_title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04512716 - MED20-165","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-08"}]